Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANTINAUSEANT WORLDWIDE MARKET VOLUME WILL REACH $182 MIL. IN 1990

Executive Summary

ANTINAUSEANT WORLDWIDE MARKET VOLUME WILL REACH $182 MIL. IN 1990, according to an estimate by SRI International in a consulting report which projects market sizes for cancer products in the U.S., Western Europe and Japan between 1980 and 1995. According to SRI calculations, antinauseants have grown at an average annual rate of 14% between 1980 and 1985. With an estimated market size of $90 mil. for 1985 and a projected average annual growth rate of 15% for the 1985-1990 period, the antinauseant class should be one of the fastest growing cancer product markets, SRI predicted. SRI suggests that a strategy that extends beyond primary therapies and into supportive and preventative care "may present opportunities for expanded penetration of the [cancer] business." The SRl report also identifies two "secondary opportunities" -- - the possibility for improving existing products -- - which relate to antinauseants: "Long-acting multiple site antinauseants [which] are used to fight the nausea and vomiting associated with chemotherapy through pharmacologic activity at multiple sites (e.g., brain, gut) within the body"; and "transdermal antinauseant delivery systems [which] are conceptually similar to transdermal analgesic systems, but deliver antinauseants over prolonged periods during lengthy courses of chemotherapy or irradiation." The report notes that "advances in supportive care (e.g., anti-infectives, antinauseants) are occurring on broad fronts, and appear likely to improve cancer treatment, toleration to therapies, and perhaps assist in improving overall survival rates. Improvements in supportive care will also enable cancer therapy to become more aggressive and thus enable it to be used in more situations than is currently possible. The SRI report is entitled Dynamics and Opportunities in Cancer Management, A similarly titled report, Dynamics and Opportunioties in Cardiovascular Medicine, Phase 2 Europe extends SRl's study of cardiovascular disease management to the principal Western European markets. Each report -- - originally prepared for a small group of SRI clients -- - is available for $15,000 from SRI International, 333 Ravenswood Ave., Melo Park, California, 94025-3493.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS008332

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel